Posted by Michael Wonder on 15 Feb 2019
EU, America and China will all get new medicines ahead of Britain after Brexit, drug company boss warns
14 February 2019 - David Meek, the CEO of Ipsen, warns Britain leaving the European Union has seen the country fall down the list of priorities.
The EU, the United States and China will get access to new medicines ahead of the UK after Brexit, the CEO of a global pharmaceutical company has said.
David Meek, the CEO of Ipsen, a leading pharmaceutical multinational, has warned that the uncertainty around Brexit and the relocation of the EMA from London to Amsterdam has meant Britain has slipped down the list of priorities when it comes to filing for approval for new drugs.
The responsibilities of the EMA will be adopted by the UK’s Medicines and Healthcare Regulatory Agency, which Mr Meek believes will now fall into less prominent category.
